ArmaGen Technologies, Inc. Hires Biotech Executive as CEO
LOS ANGELES, Jan. 3, 2013
LOS ANGELES, Jan. 3, 2013 /PRNewswire/ -- ArmaGen Technologies, Inc., a leader
in the delivery of biotherapeutics targeting the central nervous system (CNS),
today announced James Callaway, Ph.D. as Chief Executive Office and member of
the Board of Directors. Dr. Callaway was most recently President and CEO of
Cebix Inc. and joins ArmaGen with nearly 30 year of experience in
biotechnology research and development, including executive leadership
positions at Bayer and Elan Pharmaceuticals prior to joining Cebix.
"We are delighted to welcome Dr. Callaway, a respected drug developer and
biotech executive, as CEO of ArmaGen. His extensive experience working within
the realm of CNS disorders at both small biotech companies and major
pharmaceutical firms will be invaluable to ArmaGen as the company develops its
product pipeline and platform technology," said William M. Pardridge, MD,
Founder and Chief Scientific Officer of ArmaGen. "I am confident that under
his leadership, the dedicated staff at ArmaGen will be well positioned to
deliver compelling clinical data for our therapeutic candidates."
"I am honored to lead ArmaGen through this period of clinical experimentation
and validation. The potential for this proprietary Trojan horse technology to
transform the therapeutic options in the area of CNS therapies is very
exciting," said Dr. Callaway. "In addition, the specific focus on orphan drug
indications within the CNS creates a very attractive development pathway
through which to validate this platform technology."
Dr. Callaway will join Dr. Pardridge on the ArmaGen Board of Directors along
with Stuart Swiedler, MD, PhD, Martin Heidecker PhD (Boehringer Ingelheim
Venture Fund), and Arthur Tzianabos, PhD (Shire plc).
Prior to joining ArmaGen, Dr. Callaway served as President and CEO of Cebix
Inc., a biology driven company focused on reducing the sequelae associated
with diabetic peripheral neuropathy with a peptide therapeutic. Previously,
Dr. Callaway filled several executive roles during his thirteen-year tenure at
Elan Pharmaceutical, including program executive for the Alzheimer's
Immunotherapy program (encompassing 5 development candidates including
bapinuzumab and AN-1792), head of development and head of pharmaceutical
development. During his tenure at Elan he also led the development and
approval of MyoBloc®and the production of Tysabri®. Prior to Elan, Dr.
Callaway had development responsibilities at Bayer Pharmaceuticals in
Berkeley, SmithKline Beecham (GSK) in King of Prussia as well as Ingene in
Santa Monica (Xoma). Dr. Callaway received his Ph.D. in Biological Chemistry
from UCLA with a focus on peptide chemistry and has filed and defended
numerous NDAs and INDs during the course of his career.
Victoria Sergeant & Associates led the successful executive search for this
The ArmaGen molecular Trojan horse technology has the potential to re-engineer
recombinant proteins for BBB penetration for the treatment of diseases of the
brain and spinal cord. The long-term mission at ArmaGen is the development of
BBB-penetrating biopharmaceuticals for diseases of the CNS that affect over
250 million people world-wide. Initially, the company will focus on orphan
diseases of the CNS with lead biopharmaceuticals for Mucopolysaccharidosis
(MPS) Type I, or Hurler's syndrome and MPS Type II, or Hunter's disease.
ArmaGen Technologies is both a platform technology company and a products
company. The platform technology produces IgG fusion proteins formed by fusion
of a recombinant protein therapeutic, which does not cross the BBB to an IgG.
The IgG domain of the fusion protein is a genetically engineered monoclonal
antibody, which crosses the human BBB via transport on endogenous BBB
receptors. The IgG domain acts as a molecular Trojan horse to ferry the fused
pharmaceutical agent across the BBB from blood. ArmaGen has used the platform
technology to develop a diverse pipeline of BBB penetrating recombinant
protein therapeutics, including lysosomal enzymes, neurotrophins, decoy
receptors, or therapeutic antibodies.
About Victoria Sergeant & Associates
James Callaway, CEO
SOURCE ArmaGen Technologies, Inc.
Press spacebar to pause and continue. Press esc to stop.